IAS 38 : Intangible Assets Part 2 Flashcards
INTERNALLY GENERATED INTANGIBLE ASSETS
INTERNALLY GENERATED INTANGIBLE ASSETS
Internally generated goodwill 1
IAS 38 explicitly prohibits the recognition of internally generated goodwill as an asset because internally generated goodwill is neither separable nor does it arise from contractual or legal rights. [IAS 38.48]. As such, it is not an identifiable resource controlled by the entity that can be measured reliably at cost. [IAS 38.49]. It therefore does not meet the definition of an intangible asset under the standard or that of an asset under the IASB’s Conceptual Framework.
IAS 38 explicitly prohibits the recognition of internally generated goodwill as an asset because internally generated goodwill is neither separable nor does it arise from contractual or legal rights. [IAS 38.48]. As such, it is not an identifiable resource controlled by the entity that can be measured reliably at cost. [IAS 38.49]. It therefore does not meet the definition of an intangible asset under the standard or that of an asset under the IASB’s Conceptual Framework.
Internally generated goodwill 2
The standard maintains that the difference between the fair value of an entity and the carrying amount of its identifiable net assets at any time may capture a range of factors that affect the fair value of the entity, but that such differences do not represent the cost of intangible assets controlled by the entity. [IAS 38.50].
The standard maintains that the difference between the fair value of an entity and the carrying amount of its identifiable net assets at any time may capture a range of factors that affect the fair value of the entity, but that such differences do not represent the cost of intangible assets controlled by the entity. [IAS 38.50].
Internally generated intangible assets 1
The IASB recognises that it may be difficult to decide whether an internally generated intangible asset qualifies for recognition because of problems in:
(a) confirming whether and when there is an identifiable asset that will generate expected future economic benefits; and
(b) determining the cost of the asset reliably, especially in cases where the cost of generating an intangible asset internally cannot be distinguished from the cost of maintaining or enhancing the entity’s internally generated goodwill or of running day-to-day operations. [IAS 38.51].
The IASB recognises that it may be difficult to decide whether an internally generated intangible asset qualifies for recognition because of problems in:
(a) confirming whether and when there is an identifiable asset that will generate expected future economic benefits; and
(b) determining the cost of the asset reliably, especially in cases where the cost of generating an intangible asset internally cannot be distinguished from the cost of maintaining or enhancing the entity’s internally generated goodwill or of running day-to-day operations. [IAS 38.51].
Internally generated intangible assets 2
To avoid the inappropriate recognition of an asset, IAS 38 requires that internally generated intangible assets are not only tested against the general requirements for recognition and initial measurement (discussed at 3 above), but also meet criteria which confirm that the related activity is at a sufficiently advanced stage of
development, is both technically and commercially viable and includes only directly attributable costs. [IAS 38.51]. Those criteria comprise detailed guidance on accounting for intangible assets in the research phase (see below), the development phase (see below) and on components of cost of an internally generated intangible asset (see below).
To avoid the inappropriate recognition of an asset, IAS 38 requires that internally generated intangible assets are not only tested against the general requirements for recognition and initial measurement (discussed at 3 above), but also meet criteria which confirm that the related activity is at a sufficiently advanced stage of
development, is both technically and commercially viable and includes only directly attributable costs. [IAS 38.51]. Those criteria comprise detailed guidance on accounting for intangible assets in the research phase (see 6.2.1 below), the development phase (see 6.2.2 below) and on components of cost of an internally generated intangible asset (see 6.3 below).
Internally generated intangible assets 3
If the general recognition and initial measurement requirements are met, the entity classifies the generation of the internally developed asset into a research phase and a development phase. [IAS 38.52]. Only expenditure arising from the development phase can be considered for capitalisation, with all expenditure on research being recognised as an expense when it is incurred. [IAS 38.54]. If it is too difficult to distinguish an activity between a research phase and a development phase, all expenditure is treated as research. [IAS 38.53]
If the general recognition and initial measurement requirements are met, the entity classifies the generation of the internally developed asset into a research phase and a development phase. [IAS 38.52]. Only expenditure arising from the development phase can be considered for capitalisation, with all expenditure on research being recognised as an expense when it is incurred. [IAS 38.54]. If it is too difficult to distinguish an activity between a research phase and a development phase, all expenditure is treated as research. [IAS 38.53]
Internally generated intangible assets 4
Research is original and planned investigation undertaken with the prospect of gaining new scientific or technical knowledge and understanding. [IAS 38.8].
The standard gives the following examples of research activities: [IAS 38.56]
(a) activities aimed at obtaining new knowledge;
(b) the search for, evaluation and final selection of, applications of research findings or other knowledge;
(c) the search for alternatives for materials, devices, products, processes, systems or services; and
(d) the formulation, design, evaluation and final selection of possible alternatives for new or improved materials, devices, products, processes, systems or services.
Research is original and planned investigation undertaken with the prospect of gaining new scientific or technical knowledge and understanding. [IAS 38.8].
The standard gives the following examples of research activities: [IAS 38.56]
(a) activities aimed at obtaining new knowledge;
(b) the search for, evaluation and final selection of, applications of research findings or other knowledge;
(c) the search for alternatives for materials, devices, products, processes, systems or services; and
(d) the formulation, design, evaluation and final selection of possible alternatives for new or improved materials, devices, products, processes, systems or services.
Internally generated intangible assets 5
Development is the application of research findings or other knowledge to a plan or design for the production of new or substantially improved materials, devices, products, processes, systems or services before the start of commercial production or use. [IAS 38.8].
The standard gives the following examples of development activities:
(a) the design, construction and testing of pre-production or pre-use prototypes and models;
(b) the design of tools, jigs, moulds and dies involving new technology;
(c) the design, construction and operation of a pilot plant that is not of a scale economically feasible for commercial production; and
(d) the design, construction and testing of a chosen alternative for new or improved materials, devices, products, processes, systems or services. [IAS 38.59].
Development is the application of research findings or other knowledge to a plan or design for the production of new or substantially improved materials, devices, products, processes, systems or services before the start of commercial production or use. [IAS 38.8]. The standard gives the following examples of development activities:
(a) the design, construction and testing of pre-production or pre-use prototypes and models;
(b) the design of tools, jigs, moulds and dies involving new technology;
(c) the design, construction and operation of a pilot plant that is not of a scale economically feasible for commercial production; and
(d) the design, construction and testing of a chosen alternative for new or improved materials, devices, products, processes, systems or services. [IAS 38.59].
Internally generated intangible assets : Research phase
An entity cannot recognise an intangible asset arising from research or from the research phase of an internal project. Instead, any expenditure on research or the research phase of an internal project should be expensed as incurred because the entity cannot demonstrate that there is an intangible asset that will generate probable future economic benefits. [IAS 38.54-55]. If an entity cannot distinguish the research phase from the development phase, it should treat the expenditure on that project as if it were incurred in the research phase only and recognise an expense accordingly. [IAS 38.53].
An entity cannot recognise an intangible asset arising from research or from the research phase of an internal project. Instead, any expenditure on research or the
research phase of an internal project should be expensed as incurred because the entity cannot demonstrate that there is an intangible asset that will generate probable future economic benefits. [IAS 38.54-55]. If an entity cannot distinguish the research phase from the development phase, it should treat the expenditure on that project as if it were incurred in the research phase only and recognise an expense accordingly. [IAS 38.53].
Internally generated intangible assets : Development phase 1
The standard requires recognition of an intangible asset arising from development (or the development phase of an internal project) while it imposes stringent conditions that restrict recognition. These tests create a balance, ensuring that the entity does not recognise unrecoverable costs as an asset.
The standard requires recognition of an intangible asset arising from development (or the development phase of an internal project) while it imposes stringent conditions that restrict recognition. These tests create a balance, ensuring that the entity does not recognise unrecoverable costs as an asset.
Internally generated intangible assets : Development phase 2a
An intangible asset arising from development or from the development phase of an internal project should be recognised if, and only if, an entity can demonstrate all of the following:
(a) the technical feasibility of completing the intangible asset so that it will be available for use or sale;
(b) its intention to complete the intangible asset and use or sell it;
(c) its ability to use or sell the intangible asset;
An intangible asset arising from development or from the development phase of an internal project should be recognised if, and only if, an entity can demonstrate all of the following:
(a) the technical feasibility of completing the intangible asset so that it will be available for use or sale;
(b) its intention to complete the intangible asset and use or sell it;
(c) its ability to use or sell the intangible asset;
Internally generated intangible assets : Development phase 2b
(d) how the intangible asset will generate probable future economic benefits. Among other things, the entity can demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset;
(e) the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
(f) its ability to measure reliably the expenditure attributable to the intangible asset during its development. [IAS 38.57].
(d) how the intangible asset will generate probable future economic benefits. Among other things, the entity can demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset;
(e) the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
(f) its ability to measure reliably the expenditure attributable to the intangible asset during its development. [IAS 38.57].
Internally generated intangible assets : Development phase 3
The fact that an entity can demonstrate that the asset will generate probable future economic benefits distinguishes development activity from the research phase, where it is unlikely that such a demonstration would be possible. [IAS 38.58].
The fact that an entity can demonstrate that the asset will generate probable future economic benefits distinguishes development activity from the research phase, where it is unlikely that such a demonstration would be possible. [IAS 38.58].
Internally generated intangible assets : Development phase 4
It may be challenging to obtain objective evidence on each of the above conditions because:
• condition (b) relies on management intent;
• conditions (c), (e) and (f) are entity-specific (i.e. whether development expenditure meets any of these conditions depends both on the nature of the development activity itself and the financial position of the entity); and
• condition (d) above is more restrictive than is immediately apparent because the entity needs to assess the probable future economic benefits using the principles in IAS 36, i.e. using discounted cash flows. If the asset will generate economic benefits only in conjunction with other assets, the entity should apply the concept of cash-generating units. [IAS 38.60]
It may be challenging to obtain objective evidence on each of the above conditions because:
• condition (b) relies on management intent;
• conditions (c), (e) and (f) are entity-specific (i.e. whether development expenditure meets any of these conditions depends both on the nature of the development activity itself and the financial position of the entity); and
• condition (d) above is more restrictive than is immediately apparent because the entity needs to assess the probable future economic benefits using the principles in IAS 36, i.e. using discounted cash flows. If the asset will generate economic benefits only in conjunction with other assets, the entity should apply the concept of cash-generating units. [IAS 38.60]
Internally generated intangible assets : Development phase 5
IAS 38 indicates that evidence may be available in the form of:
• a business plan showing the technical, financial and other resources needed and the entity’s ability to secure those resources;
• a lender’s indication of its willingness to fund the plan confirming the availability of external finance; [IAS 38.61] and
• detailed project information demonstrating that an entity’s costing systems can measure reliably the cost of generating an intangible asset internally, such as salary and other expenditure incurred in securing copyrights or licences or developing computer software. [IAS 38.62].
IAS 38 indicates that evidence may be available in the form of:
• a business plan showing the technical, financial and other resources needed and the entity’s ability to secure those resources;
• a lender’s indication of its willingness to fund the plan confirming the availability of external finance; [IAS 38.61] and
• detailed project information demonstrating that an entity’s costing systems can measure reliably the cost of generating an intangible asset internally, such as salary and other expenditure incurred in securing copyrights or licences or developing computer software. [IAS 38.62].
Internally generated intangible assets : Development phase 6
Certain types of product (e.g. pharmaceuticals, aircraft and electrical equipment) require regulatory approval before they can be sold. Regulatory approval is not one of the criteria for recognition under IAS 38 and the standard does not prohibit an entity from capitalising its development costs in advance of approval. However, in some industries regulatory approval is vital to commercial success and its absence indicates significant uncertainty around the possible future economic benefits. This is the case in the pharmaceuticals industry, where it is rarely possible to determine whether a new drug will secure regulatory approval until it is actually granted. Accordingly, it is common practice in this industry for costs to be expensed until such approval is obtained.
Certain types of product (e.g. pharmaceuticals, aircraft and electrical equipment) require regulatory approval before they can be sold. Regulatory approval is not one of the criteria for recognition under IAS 38 and the standard does not prohibit an entity from capitalising its development costs in advance of approval. However, in some industries regulatory approval is vital to commercial success and its absence indicates significant uncertainty around the possible future economic benefits. This is the case in the pharmaceuticals industry, where it is rarely possible to determine whether a new drug will secure regulatory approval until it is actually granted. Accordingly, it is common practice in this industry for costs to be expensed until such approval is obtained.
Internally generated intangible assets : Development phase 7
The standard does not define the terms ‘research phase’ and ‘development phase’ but explains that they should be interpreted more broadly than ‘research’ and ‘development’ which it does define. [IAS 38.52]. The features characterising the research phase have less to do with what activities are performed, but relate more to an inability to demonstrate at that time that there is an intangible asset that will generate probable future benefits. [IAS 38.55]. This means that the research phase may include activities that do not necessarily meet the definition of ‘research’.
The standard does not define the terms ‘research phase’ and ‘development phase’ but explains that they should be interpreted more broadly than ‘research’ and
‘development’ which it does define. [IAS 38.52]. The features characterising the research phase have less to do with what activities are performed, but relate more
to an inability to demonstrate at that time that there is an intangible asset that will generate probable future benefits. [IAS 38.55]. This means that the research phase may include activities that do not necessarily meet the definition of ‘research’.
Internally generated intangible assets : Development phase 8
For example, the research phase for IAS 38 purposes may extend to the whole period preceding a product launch, regardless of the fact that activities that would
otherwise characterise development are taking place at the same time, because certain features that would mean the project has entered its development phase are still absent (such as confirming an ability to use or sell the asset; demonstrating sufficient market demand for a product; or uncertainty regarding the source of funds to complete the project).
For example, the research phase for IAS 38 purposes may extend to the whole period preceding a product launch, regardless of the fact that activities that would
otherwise characterise development are taking place at the same time, because certain features that would mean the project has entered its development phase are still absent (such as confirming an ability to use or sell the asset; demonstrating sufficient market demand for a product; or uncertainty regarding the source of funds to complete the project).
Internally generated intangible assets : Development phase 9
As a result, an entity might not be able to distinguish the research phase from the development phase of an internal project to create an intangible asset, in which case it should treat the expenditure on that project as if it were incurred in the research phase only and recognise an expense accordingly. [IAS 38.53]. It also means that the development phase may include activities that do not necessarily meet the definition of ‘development’. The example below illustrates how an entity would apply these rules in practice (Example 17.6: Research phase and development phase under IAS 38 on OneNote)
As a result, an entity might not be able to distinguish the research phase from the development phase of an internal project to create an intangible asset, in which case it should treat the expenditure on that project as if it were incurred in the research phase only and recognise an expense accordingly. [IAS 38.53]. It also means that the development phase may include activities that do not necessarily meet the definition of ‘development’. The example below illustrates how an entity would apply these rules in practice (Example 17.6: Research phase and development phase under IAS 38 on OneNote)
Internally generated intangible assets : Development phase 10
The difficulty in applying the IAS 38 recognition criteria for development costs in the pharmaceutical industry are discussed further at 6.2.3 below. Technical and economic feasibility are typically established very late in the process of developing a new product, which means that usually only a small proportion of the development costs is capitalised. When the development phase ends will also influence how the entity recognises revenue from the project.
The difficulty in applying the IAS 38 recognition criteria for development costs in the pharmaceutical industry are discussed further at 6.2.3 below. Technical and economic feasibility are typically established very late in the process of developing a new product, which means that usually only a small proportion of the development costs is capitalised. When the development phase ends will also influence how the entity recognises revenue from the project.
Internally generated intangible assets : Development phase 11
As noted at 4.4 above, during the development phase an entity can only recognise income from incidental operations, being those not necessary to develop the asset for its intended use, as revenue in profit or loss. [IAS 38.31]. During the phase in which the activity is necessary to bring the intangible asset into its intended use, any income should be deducted from the cost of the development asset. Examples include income from the sale of samples produced during the testing of a new process or from the sale of a production prototype. Only once it is determined that the intangible asset is ready for its intended use would revenue be recognised from such activities. At
the same time capitalisation of costs would cease and the related costs of the revenue generating activity would include a measure of amortisation of the asset.
As noted at 4.4 above, during the development phase an entity can only recognise income from incidental operations, being those not necessary to develop the asset for its intended use, as revenue in profit or loss. [IAS 38.31]. During the phase in which the activity is necessary to bring the intangible asset into its intended
use, any income should be deducted from the cost of the development asset. Examples include income from the sale of samples produced during the testing of a new process or from the sale of a production prototype. Only once it is determined that the intangible asset is ready for its intended use would revenue be recognised from such activities. At the same time capitalisation of costs would cease and the related costs of the revenue generating activity would include a measure of amortisation of the asset.
Internally generated intangible assets : Research and development in the pharmaceutical industry 1
Entities in the pharmaceutical industry consider research and development to be of primary importance to their business. Consequently, these entities spend a considerable amount on research and development every year and one might expect them to carry significant internally generated development intangible assets on their statement of financial position. However, their financial statements reveal that they often consider the uncertainties in the development of pharmaceuticals to be too great to permit capitalisation of development costs.
Entities in the pharmaceutical industry consider research and development to be of primary importance to their business. Consequently, these entities spend a considerable amount on research and development every year and one might expect them to carry
significant internally generated development intangible assets on their statement of financial position. However, their financial statements reveal that they often consider the uncertainties in the development of pharmaceuticals to be too great to permit capitalisation of development costs.
Internally generated intangible assets : Research and development in the pharmaceutical industry 2
One of the problems is that, in the case of true ‘development’ activities in the pharmaceutical industry, the final outcome can be uncertain and the technical and economic feasibility of new products or processes is typically established very late in the development phase, which means that only a small proportion of the total development costs can ever be capitalised. In particular, many products and processes require approval by a regulator such as the US Food and Drug Administration (FDA) before they can be applied commercially and until that time the entity may be uncertain of their success. After approval, of course, there is often relatively little in the way of further development expenditure.
One of the problems is that, in the case of true ‘development’ activities in the pharmaceutical industry, the final outcome can be uncertain and the technical and economic feasibility of new products or processes is typically established very late in the development phase, which means that only a small proportion of the total development costs can ever be capitalised. In particular, many products and processes require approval by a regulator such as the US Food and Drug Administration (FDA) before they can be applied commercially and until that time the entity may be uncertain of their success. After approval, of course,
there is often relatively little in the way of further development expenditure.
Internally generated intangible assets : Research and development in the pharmaceutical industry 3
In the pharmaceutical sector, the capitalisation of development costs for new products or processes usually begins at the date on which the product or process receives regulatory approval. In most cases that is the point when the IAS 38 criteria for recognition of intangible assets are met. It is unlikely that these criteria will have been met before approval is granted by the regulator.
In the pharmaceutical sector, the capitalisation of development costs for new products or processes usually begins at the date on which the product or process receives regulatory approval. In most cases that is the point when the IAS 38 criteria for recognition of intangible assets are met. It is unlikely that these criteria will have been met before approval is granted by the regulator.